4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Transgene SA (TNG) operates in the Biotechnology industry and is headquartered in Illkirch-Graffenstaden, France with about 145 employees. Its market capitalization is roughly €239 million. In the fiscal year ended 2025-12-31, TNG reported €0M in revenue and (€38M) in net income.
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €0M | €0M | €1M | €4M | — |
| Operating Income (EBIT) | (€34M) | (€36M) | (€29M) | (€30M) | — |
| Net Income | (€38M) | (€34M) | (€22M) | (€33M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €139M | €42M | €45M | €66M | — |
| Total Liabilities | €17M | €27M | €30M | €29M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TNG viewer.
About TickerBase · Data methodology & sources · Privacy · Terms